Picture [LSUS] – The Business Web Portal 600x60px
Document › Details

Adaptimmune Therapeutics plc. (2/27/19). "Press Release: CORRECTING and REPLACING -- Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update". Philadeliphia, PA & Oxford.

Organisations Organisation Adaptimmune Therapeutics plc (Nasdaq: ADAP)
  Group Adaptimmune (Group)
  Organisation 2 M. D. Anderson Cancer Center
  Group University of Texas System
Products Product MAGE-A10 SPEAR™ T-cell therapy
  Product 2 MAGE-A4 SPEAR™ T-cell therapy
Persons Person Noble, James (Adaptimmune 201909– Non-Executive Director before CEO before MediGene + Avidex)
  Person 2 Amado, Rafael G. (Allogene 201909– EVP RnD + CMO before Adaptimmune + GSK + Amgen + UCLA)

Record changed: 2019-07-30


Picture [LSA] – The Business Web Portal 650x89px

More documents for Adaptimmune (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BIO-Europe 2019 Hamburg Germany BEU2019 650x80px

» top